Infections in AIDS

Journal of Medical Microbiology

Volumn 49, Issue 11, 2000, Pages 947-967

  Hart, C A ^a   Beeching, N J ^a   Duerden, B I ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ASTEMIZOLE; CISAPRIDE; CLARITHROMYCIN; COTRIMOXAZOLE; CYTOCHROME P450 3A; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ERYTHROMYCIN; FLUCONAZOLE; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TERFENADINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL COLONIZATION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE TRANSMISSION; DRUG FORMULATION; DRUG METABOLISM; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MICROSPORIDA; MICROSPORIDIOSIS; MORBIDITY; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOGENICITY; PRIORITY JOURNAL; SALMONELLA ENTERICA; SALMONELLOSIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0033760687     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-49-11-947     Document Type: Conference Paper

References (237)

1. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California
2. Epidemiology of sexually transmitted infections and AIDS in developing countries
3. HIV-1 disease progression in AIDS-defining disorders in rural Uganda
4. Clinical presentation and outcome of Pneumocystis carinii pneumonia in Malawian children
5. Disease in children infected with HIV in Abidjan, Cote d'Ivoire
6. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
7. Changing patterns of mortality across Europe in patients infected with HIV-1
8. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with human immunodeficiency virus
9. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus
10. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection
11. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1
12. Viral dynamics in human immunodeficiency virus type 1 infection
13. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
14. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to Zidovudine (AZT)
15. HIV-1 drug resistance in newly infected individuals
16. Discontinuation of prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
17. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
18. Human immunodeficiency virus type I in the semen of men receiving highly active antiretroviral therapy
19. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
20. Hidden dangers of incompletely suppressive antiretroviral therapy
21. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society - USA Panel
22. Drug resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trial
23. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
24. Microsporidia
25. High seroprevalence of Encephalitozoon species in immunocompetent subjects
26. Occurrence of a new microsporidian: Enterocytozoon bieneusi n. g., n. sp., in the enterocytes of a human patient with AIDS
27. Clinical features of microsporidiosis in patients with AIDS
28. Septata intestinalis N.G.N.Sp., an intestinal microsporidian associated with chronic diarrhea and dissemination in AIDS patients
29. Simultaneous infection with two types of intestinal microsporidia in a patient with AIDS
30. Human microsporidial infections
31. Identification of Enterocytozoon bieneusi spores in respiratory samples from an AIDS patient with a 2-year history of intestinal microsporidiosis
32. Clinical significance of small-intestinal microsporidiosis in HIV-1-infected individuals
33. The prevalence of Enterocytozoon bieneusi in acquired immunodeficiency syndrome (AIDS) patients from the north west of England: 1992-1995
34. The role of microsporidia in the pathogenesis of HIV-related chronic diarrhea
35. Isolation and characterization of a new microsporidian, Encephalitozoon hellem (n. sp.), from three AIDS patients with keratoconjunctivitis
36. Microsporidial keratoconjunctivitis in a patient with AIDS
37. Pathology of symptomatic microsporidial (Encephalitozoon hellem) bronchiolitis in the acquired immunodeficiency syndrome: A new respiratory pathogen diagnosed from lung biopsy, bronchoalveolar lavage, sputum, and tissue culture
38. Human microsporidiosis
39. Vittaforma corneae n. comb. for the human microsporidium Nosema corneum Shadduck, Meccoli, Davis and Font, 1990, based on its ultrastructure in the liver of experimentally infected athymic mice
40. Isolation of a microsporidian from a human patient
41. Experimental infection of athymic mice with the human microsporidian Nosema corneum
42. Dual microsporidian infection due to Vittaforma corneae and Encephalitozoon hellem in a patient with AIDS
43. Myositis due to Pleistophora (microsporidia) in a patient with AIDS
44. Microsporidiosis myositis in a patient with the acquired immunodeficiency syndrome
45. Myositis associated with a newly described microsporidian, Trachipleistophora hominis, in a patient with AIDS
46. Development and ultrastructure of Trachipleistophora hominis n.g., n.sp. after in vitro isolation from an AIDS patient and inoculation into athymic mice
47. Brachiola vesicularum, n. g., n. sp., a new microsporidian associated with AIDS and myositis
48. Microsporidia of the genus Trachipleistophora - Causative agents of human microsporidiosis: Description of Trachipleistophora anthropophthera N. Sp. (Protozoa: Microsporidia)
49. Pathology of microsporidiosis: Emerging parasitic infections in patients with acquired immunodeficiency syndrome
50. In vitro growth of the microsporidian Septata intestinalis from an AIDS patient with disseminated illness
51. Murine encephalitozoonosis model for studying the host-parasite relationship of a chronic infection
52. Disseminated microsporidiosis (Encephalitozoon hellem) and acquired immunodeficiency syndrome. Autopsy evidence for respiratory acquisition
53. A microsporidian isolated from an AIDS patient corresponds to Encephalitozoon cuniculi III, originally isolated from domestic dogs
54. Encephalitozoon hellem in budgerigars (Melopsittacus undulatus)
55. Encephalitozoon hellem in two Eclectus Parrots (Eclectus roratus): Identification from archival tissues
56. Immunologic and molecular characteristics of Encephalitozoon-like microsporidia isolated from humans and rabbits indicate that Encephalitozoon cuniculi is a zoonotic parasite
57. Genetic evidence for latent Septata intestinalis infection in human immunodeficiency virus-infected patients with intestinal microsporidiosis
58. Immunologic, microscopic, and molecular evidence of Encephalitozoon intestinalis (Septata intestinalis) infection in mammals other than humans
59. Molecular epidemiology of Encephalitozoon cuniculi and first detection of Enterocytozoon bieneusi in faecal samples of pigs
60. Localization of persistent Enterocytozoon bieneusi infection in normal rhesus macaques (Macaca mulatta) to the hepatobiliary tree
61. Determination of types of Enterocytozoon bieneusi strains isolated from patients with intestinal microsporidiosis
62. Opportunistic properties of Nosema algerae (Microspora), a mosquito parasite, in immunocompromised mice
63. Staining of microsporidian spores by optical brighteners with remarks on the use of brighteners for the diagnosis of AIDS associated human microsporidioses
64. Improved light-microscopical detection of microsporidia spores in stool and duodenal aspirates
65. Relevant criteria for detecting microsporidia in stool specimens
66. Simple diagnosis of Encephalitozoon sp. microsporidial infections by using a panspecific antiexospore monoclonal antibody
67. Human microsporidioses
68. Treatment of intestinal microsporidiosis with albendazole in patients with AIDS
69. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: Clinical features and response to albendazole therapy
70. Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: A randomized double-blind controlled trial
71. Activity of albendazole against Encephalitozoon cuniculi in vitro
72. Polymerase chain reaction and culture confirmation of disseminated Encephalitozoon cuniculi in a patient with AIDS: Successful therapy with albendazole
73. Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro
74. Treatment of microsporidial keratoconjunctivitis with topical fumagillin
75. Potential efficacy of fumagillin in intestinal microsporidiosis due to Enterocytozoon bieneusi in patients with HIV infection: Results of a drug screening study. The French Microsporidiosis Study Group
76. TNP-470 is an effective antimicrosporidial agent
77. Thalidomide: A novel therapy for microsporidiosis
78. Antiretroviral treatment in 1998
79. Remission of AIDS-associated intestinal microsporidiosis with highly active antiretroviral therapy
80. Enterocytozoon bieneusi as a cause of chronic diarrhea in a heart-lung transplant recipient who was seronegative for human immunodeficiency virus
81. Intestinal microsporidiosis occurring in a liver transplant recipient
82. Enterocytozoon bieneusi infection and diarrheal disease in patients who were not infected with human immunodeficiency virus: Case report and review
83. Enterocytozoon bieneusi infection in an immunocompetent patient who had acute diarrhea and who was not infected with the human immunodeficiency virus
84. Self-limited traveller's diarrhea due to a dual infection with Enterocytozoon bieneusi and Cryptosporidium parvum in an immunocompetent HIV-negative child
85. Identification of Encephalitozoon intestinalis in travelers with chronic diarrhea by specific PCR amplification
86. Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex
87. A larger spectrum of severe HIV-1-related disease in intravenous drug users in New York City
88. Autopsy patterns of disease among subgroups of an inner-city Bronx AIDS population
89. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS
90. Causes of fever in patients infected with human immunodeficiency virus who were admitted to Boston City Hospital
91. Community-acquired bacteremia in patients with acquired immunodeficiency syndrome: Clinical presentation, bacteriology, and outcome
92. Frequencies of opportunistic diseases prior to death among HIV-infected persons. Community programs for clinical research on AIDS
93. Bacterial pneumonia in persons infected with the human immunodeficiency virus
94. Community-acquired pneumonia: Impact of immune status
95. Bacterial pneumonia in patients with the acquired immunodeficiency syndrome
96. Respiratory illness in persons with Human Immunodeficiency Virus infection
97. Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya
98. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya
99. Community acquired pneumonia in adults in Addis Ababa: Etiologic agents and the impact of HIV infection
100. Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV-infected adults in Abidjan, Cote d'Ivoire
101. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population
102. Sinusitis in patients with the acquired immunodeficiency syndrome
103. Bacterial bronchitis and bronchiectasis in human immunodeficiency virus infection
104. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: Incidence, etiologies, and clinical aspects
105. Increasing morbidity without rise in non-AIDS mortality among HIV-infected intravenous drug users in Amsterdam
106. The presentation and outcome of HIV-related disease in Nairobi
107. Microbiology of community-acquired bacterial pneumonia in persons with and at risk for human immunodeficiency virus type 1 infection. Implications for rational empiric antibiotic therapy
108. Bacterial pneumonia in HIV-infected patients: Analysis of risk factors and prognostic indicators
109. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents
110. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population
111. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia
112. Pneumococcal bacteremia in Charleston County, South Carolina. A decade later
113. Pneumococcal pneumonia in adult hospitalized patients infected with the human immunodeficiency virus
114. Pneumococcal bacteremia with pneumonia. Mortality in acquired immunodeficiency syndrome
115. Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994
116. Invasive pneumococcal disease: Clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection
117. Bacterial pneumonia in the HIV-infected patient
118. Impact of febrile illness among patients wth HIV-1 disease in Uganda
119. Lack of efficacy of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults
120. Unusual manifestations of pneumococcal infection in human immunodeficiency virus-infected individuals: The past revisited
121. Invasive pneumococcal disease in the immunocompromised host
122. Pyogenic brain abscess caused by Streptococcus pneumoniae: Case report and review
123. Streptococcus pneumoniae blood culture isolates from patients with and without Human Immunodeficiency Virus infection: Alterations in penicillin susceptibilities and in serogroups or serotypes
124. Streptococcus pneumoniae resistant to penicillin and tetracycline associated with HIV seropositivity
125. Serotype distribution and prevalence of resistance to benzylpenicillin in three representative populations of Streptococcus pneumoniae isolates from the coast of Kenya
126. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus
127. Bacterial pneumonia in adult populations with Human Immunodeficiency Virus (HIV) infection
128. Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine
129. Pneumococcal vaccination in HIV-1-infected adults in Uganda: Humoral response and two vaccine failures
130. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients
131. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1
132. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine
133. Equal IgG antibody response to pneumococcal vaccination in all stages of human immunodeficiency virus disease
134. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: Results from a randomized trial
135. Community-acquired bacteremia in HIV-positive patients: Protective benefit of co-trimoxazole
136. The effect of Pneumocystis carinii pneumonia prophylaxis regimens on the incidence of bacterial infections in HIV-infected patients
137. Secondary Pneumocystis carinii pneumonia prophylaxis with trimethoprim-sulphamethoxazole does not prevent bacterial pneumonia in HIV-infected persons
138. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients
139. Early Co-trimoxazole chemoprophylaxis for HIV-infected adults in Africa: A double blind placebo-controlled trial, Abidjan, Ivory Coast
140. Significant reduction in mortality attributable to co-trimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Ivory Coast
141. Salmonella bacteremia in the first year of life
142. Salmonella enteritidis bacteremia in childhood
143. Community-acquired bacteraemia in African children
144. Plasmodium falciparum malaria and salmonella infections in Gambian children
145. Salmonella bacteraemia among young children at a rural hospital in western Zaire
146. The clinical presentation of non-typhoidal salmonella bacteraemia in Malawian children
147. Non-typhoidal salmonella septicemia in Gabonese children infected with Schistosoma intercalatum
148. Pathogens and predictors of fatal septicemia associated with human immunodeficiency virus infection in Ivory Coast, West Africa
149. Multi-drug resistant non-typhi salmonellae in Kenya
150. Salmonella bacteremia in African patients with human immunodeficiency virus infection
151. Bacteraemia and mortality among adult medical admissions in Malawi - Predominance of non-typhi salmonellae and Streptococcus pneumoniae
152. Relationship between human immunodeficiency virus infection and salmonellosis in 20- to 59-year-old residents of New York City
153. Epidemiology of non-typhoidal Salmonella bacteremia during the human immunodeficiency virus epidemic
154. Infectious endocarditis due to non-typhi Salmonella in patients with human immunodeficiency virus: Report of two cases and review
155. Nontyphoidal Salmonella intracranial infections in HIV-infected patients
156. Salmonellosis during infection with human immunodeficiency virus
157. Salmonella lung involvement in patients with HIV infection
158. Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients
159. The epidemiology of Salmonella typhimurium in cattle: Plasmid profile analysis of definitive phage type (DT) 204c
160. Associations between human and farm animal infections with Salmonella typhimurium DT 104 in Herefordshire
161. Food and milk-borne zoonotic infections
162. Analysis of Salmonella enterica serotype Typhimurium by phage typing, antimicrobial susceptibility and pulsed-field gel electrophoresis
163. Epidemic in cattle and humans of Salmonella typhimurium DT 104 with chromosomally integrated multiple drug resistance
164. Resistance to ciprofloxacin in non-typhoidal salmonellae in England and Wales. The current situation
165. Pathogenicity islands of virulent bacteria: Structure, function and impact on microbial evolution
166. Type III protein secretion systems in bacterial pathogens of animals and plants
167. A 40 kb chromosomal fragment encoding Salmonella typhimurium invasion genes is absent from the corresponding region of the Escherichia coli K-12 chromosome
168. Identification of a virulence locus encoding a second type III secretion system in Salmonella typhimurium
169. The Salmonella selC locus contains a pathogenicity island mediating intramacrophage survival
170. Identification and sequence analysis of a 27-kilobase chromosomal fragment containing a Salmonella pathogenicity island located at 92 minutes on the chromosome map of Salmonelia enterica serovar Typhimurium LT2
171. Identification of a pathogenicity island required for Salmonella enteropathogenicity
172. Salmonella septicaemias in Kenyan children
173. Oropharyngeal microflora in Aboriginal and non-Aboriginal Australian children: An indicator of environmental contamination
174. Oro-pharyngeal microflora in malnourished children
175. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes
176. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients
177. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection
178. Impaired interleukin 12 production in human immunodeficiency virus-infected patients
179. Role of interleukin-10 in T-helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus
180. Localization of Nrampl in macrophages: Modulation with activation and infection
181. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of an International AID5 Society - USA Panel
182. Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use
183. Clinical pharmacokinetics of nucleoside anti-retroviral agents
184. Abacavir
185. Clinical pharmacokinetics of zidovudine: An update
186. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes
187. Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations
188. Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus
189. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase
190. Antiretroviral drugs for AIDS
191. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells
192. Drug interactions with zidovudine phosphorylation in vitro
193. Zalcitabine (ddC) phosphorylation and drug interactions
194. Lamivudine (3TC) phosphorylation and drug interactions in vitro
195. Anti-human immunodeficiency virus type-1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides
196. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
197. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease
198. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
199. Disposition and bioavailability of the HIV-proteinase inhibitor, Ro 31-8959, after single doses in healthy volunteers
200. Enzyme induction and inhibition
201. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes
202. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
203. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients
204. Nevirapine: A review of its development, pharmacological profile and potential for clinical use
205. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir
206. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection
207. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues
208. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and p-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
209. Effects of imidazole derivatives on cytochrome P450 from human hepatocytes in primary culture
210. Evaluation of potential ritonavir and indinavir combination BID regimens
211. Investigations of nelfinavir mesylate (NFV) pharmacokinetic (PK) interactions with indinavir (IDV) and ritonavir (RTV)
212. Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients
213. Ritonavir
214. Prediction of in vivo impairment of cytochrome P450-mediated metabolism by HIV protease inhibitors
215. Pharmacokinetics of an indinavir/ritonavir 800/100mg BID regimen
216. Pharmacokinetics of 141W94 and indinavir (IDV) after single-dose coadministration in HIV-positive volunteers
217. Nelfinavir: A review of its therapeutic efficacy in HIV infection
218. Plasma metabolites of nelfinavir, a potent HIV protease inhibitor, in HIV positive patients: Quantification by LC-MS/MS and antiviral activities
219. Delavirdine (DLV) and nelfinavir (NFV); a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers
220. Pharmacokinetics drug interactions with amprenavir
221. Effect of efavirenz (DMP266) on the pharmacokinetics of 141W94 in HIV infected patients
222. Effect of the reverse transcriptase inhibitor, nevaripine, on the steady state pharmacokinetics of clarithromycin in HIV positive patients
223. Delavidine (DLV) and indinavir (IDV); a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers
224. Delavirdine (DLV) mesylate pharmacokinetics (PK) during combination therapy with ritonavir (RIT)
225. Pharmacokinetic (PK) evaluation of saquinavir soft gel capsules (SQV)/ritonavir (RTV) or SQV/nelfinavir in combination with delavirdine (DLV) and/or adefovir dipivoxil (ADV) - ACTG 359
226. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infections
227. Pharmacokinetic interaction between efevirenz (EFV) and nelfmavir mesylate (NFV) in healthy volunteers
228. Pharmacokinetics of efavirenz (EFV) and ritonavir (RIT) after multiple oral doses in healthy volunteers